Recent developments for Prenetics include financial results announcements, executive appointments, share repurchase authorization, and analyst coverage.

• Prenetics held its Q1 2026 earnings call and published the transcript and highlights in May 2026, providing updates on operational and financial performance [N1][N2].
• Brian Rosin was appointed as US CFO of the IM8 brand in May 2026, indicating a focus on strengthening financial leadership for this segment [N3].
• The company's board authorized a share repurchase program in March 2026, reflecting capital allocation decisions [N5].
• Lake Street initiated coverage of Prenetics with a buy recommendation in March 2026, and Cantor Fitzgerald maintained an overweight recommendation in October 2025, indicating positive analyst sentiment [N4][N6].
• Prenetics divested ACT Genomics in mid-2025, which strengthened its financial position and raised its revenue outlook for FY2025 [N8].
• The company reported 93.5% revenue growth in Q4 2024 and provided financial guidance for 2025, highlighting significant recent growth [N8].

Prenetics has demonstrated the ability to scale operations rapidly, as evidenced by its COVID-19 testing volume and revenue generation during the pandemic. The company's strategic divestment of non-core assets and focus on the IM8 health and longevity brand indicate a streamlined business model. Recent executive appointments and share repurchase authorization suggest active management and capital allocation. The company's liquidity position, with a current ratio above 2, supports operational flexibility. Continued revenue growth and market recognition through analyst coverage may enhance visibility and investor interest.

Prenetics continues to report net losses and negative earnings per share, reflecting ongoing challenges in achieving profitability. The company operates in a competitive health and wellness market with evolving consumer preferences and regulatory environments. Non-cash items such as fair value losses on digital assets and warrant liabilities introduce volatility in reported results. The divestment of certain businesses and discontinuation of COVID-19 testing services may impact revenue diversification. Dependence on key executives and the need for sustained innovation pose execution risks. Market conditions and operational execution will influence the company's ability to improve financial performance.

Prenetics' moat is anchored in its established brand presence in health and longevity, particularly through its IM8 brand co-founded with a high-profile partner, David Beckham. The company's extensive experience in large-scale genetic testing during the COVID-19 pandemic provided operational scale and data assets. Its leadership team combines expertise in healthcare, investment, and consumer markets, supporting innovation and market expansion. The company's scientific advisory board and focus on data-driven wellness protocols contribute to product credibility. However, the health and wellness sector is competitive and rapidly evolving, requiring continuous innovation and brand differentiation to maintain competitive advantage.

• Profitability and Cash Flow Risk: Prenetics reported significant net losses and negative EPS for recent fiscal years, indicating ongoing challenges in achieving profitability and positive cash flow.
• Market Competition and Innovation Risk: The health and longevity sector is competitive and rapidly evolving, requiring continuous innovation and effective marketing to maintain market share.
• Regulatory and Operational Risks: Changes in healthcare regulations, data privacy laws, and operational execution could materially affect business performance.
• Financial Volatility from Non-Cash Items: Fair value changes on digital assets and warrant liabilities introduce volatility in reported earnings, which do not impact cash flows but affect financial statements.
• Dependence on Key Personnel: The company relies on experienced executives and scientific advisors; turnover or loss of key personnel could impact strategic direction and operations.

• Prenetics Global Ltd is a company publicly traded under ticker PRE.
• The company operates a flagship health and longevity brand called IM8, which is wholly owned by Prenetics and co-founded with David Beckham.
• Prenetics performed 28 million COVID-19 tests and generated approximately $700 million in revenue during the pandemic.
• The company completed a public listing on the Nasdaq Stock Exchange.
• Prenetics reported revenue of approximately $21.7 million for the year ended December 31, 2023, and a net loss of approximately $49.8 million for the year ended December 31, 2024, according to the latest 20-F filing.
• Basic and diluted earnings per share were negative $3.71 for the year ended December 31, 2024.
• As of December 31, 2024, Prenetics had cash and cash equivalents of approximately $52.3 million and current assets of about $86.1 million, with current liabilities of approximately $36.6 million, resulting in a current ratio of 2.36 and a cash ratio of 1.43.
• The company has a board of directors consisting of four members, including CEO and Chairperson Danny Sheng Wu Yeung, independent directors, and a CFO overseeing financial operations.
• Prenetics has a 2022 Share Incentive Plan allowing issuance of shares and awards to employees, directors, and consultants.
• The company divested ACT Genomics in 2025, strengthening its financial position and raising its FY2025 revenue outlook.
• Prenetics appointed Brian Rosin as US CFO of IM8 in May 2026.
• The company authorized a share repurchase program in March 2026.
• Recent earnings calls and highlights were published in May 2026, providing operational updates.
• Prenetics has received buy and overweight recommendations from Lake Street and Cantor Fitzgerald respectively in 2026 and 2025.
• The company experienced significant revenue growth in Q4 2024, reporting 93.5% growth and provided financial guidance for 2025.
• Prenetics' leadership includes executives with backgrounds in healthcare, investment banking, and consumer brands.
• The company uses IFRS accounting standards and discloses significant estimates and judgments in asset impairment and valuation of warrant liabilities.
• Prenetics' financial results include non-IFRS measures such as adjusted EBITDA to supplement IFRS results.
• The company has experienced losses from discontinued operations related to cessation of COVID-19 diagnostic services and disposal of certain businesses.
• Prenetics holds digital assets including Bitcoin, with unrealized fair value losses reported in 2025.
• The company has a scientific advisory board for its IM8 brand, including appointments announced in 2025.
• Prenetics' executive officers have employment agreements with confidentiality, non-competition, and indemnification provisions.